Nasdaq · Biotech stocks database
HCM — HUTCHMED (China) Limited
HCM (HUTCHMED (China) Limited) stock: $14.18, $2.47B market cap, $1.37B cash, $1.11B EV, $2.47B fully diluted market cap. Next expected readout: Oct-26. Lead program: HMPL-760 (Relapsed/Refractory Diffuse Large B-Cell Lymphoma), Phase 3. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Enterprise value
$1,106.6M
Balance sheet
Cash $1,367.3M Debt $0.0M Net cash $1,367.3M Enterprise value $1,106.6M Basic shares 174.4M shares Fully diluted shares 174.5M shares Fully diluted market cap $2,473.9M Cash per share $7.84
Cash figures as of 2025-12-31. Database snapshot: 2026-09-22.
Price history Loading HCM daily closes…
Loading price history…
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Nov 12 - Dec 24 HMPL-760 Phase 1 Healthy Participants — Jan 12 - Feb 23 HMPL-306 Phase 1 Gliomas Harboring IDH1 and/or IDH2 Mutations — Nov 19 - Dec 31 HMPL-506 Phase 1 Hematological Malignancies — Jun 11 - Jul 23 HMPL-760 Phase 3 Relapsed/Refractory Diffuse Large B-Cell Lymphoma — Jul 11 - Aug 22 Savolitinib Phase 3 Non-small Cell Lung Cancer — Jul 12 - Aug 23 Nab-paclitaxel Plus Gemcitabine Phase 3 Metastatic Pancreatic Cancer — Aug 7 - Sep 18 HMPL-A830 Phase 2 Solid Tumor, Adult — Aug 11 - Sep 22 HMPL-453 Phase 3 Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult — Jan 11 - Feb 22 HMPL-A251 Phase 2 Solid Tumors, Adult — Feb 11 - Mar 25 HMPL-306 Regimen Phase 3 Acute Myeloid Leukemia — Feb 11 - Mar 25 HMPL-A580 Phase 2 Solid Tumors, Adult — Feb 19 - Apr 2 fruquintinib Phase 3 Advanced Endometrial Cancer —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
Pipeline Lead drug HMPL-760 Lead indication Relapsed/Refractory Diffuse Large B-Cell Lymphoma Lead phase Phase 3 Active trials 15
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07409428 Phase 3 Recruiting Sponsor HCM — Relapsed/Refractory Diffuse Large B-Cell Lymphoma — NCT05009836 Phase 3 Active, not recruiting Sponsor HCM — Non-small Cell Lung Cancer — NCT06361888 Phase 3 Recruiting Sponsor HCM — Metastatic Pancreatic Cancer — NCT04353375 Phase 3 Recruiting Sponsor HCM — Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult — NCT06387069 Phase 3 Recruiting Sponsor HCM — Acute Myeloid Leukemia — NCT06584032 Phase 3 Recruiting Sponsor HCM — Advanced Endometrial Cancer — NCT05522231 Phase 3 Active, not recruiting Sponsor HCM — Advanced Renal Cell Carcinoma — NCT05535933 Phase 3 Active, not recruiting Sponsor HCM — Warm Antibody Autoimmune Hemolytic Anemia — NCT07718581 Phase 2 Not yet recruiting Sponsor HCM — Solid Tumor, Adult — NCT07228247 Phase 2 Recruiting Sponsor HCM — Solid Tumors, Adult — NCT07396584 Phase 2 Recruiting Sponsor HCM — Solid Tumors, Adult — NCT06601504 Phase 2 Active, not recruiting Sponsor HCM — Relapsed/Refractory Diffuse Large B-Cell Lymphoma —
Sponsor-matched active trials from ClinicalTrials.gov (15 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 15 active trials for Hutchmed on ClinicalTrials.gov
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.